Streetbeat News

Price Targets

AKTS

Piper Sandler analyst Harsh Kumar has downgraded Akoustis Technologies (NASDAQ:AKTS) from Overweight to Neutral and reduced the price target from $2 to $1.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 10:30 am

AAPL

Piper Sandler analyst Harsh Kumar has downgraded Apple (AAPL) from Overweight to Neutral and reduced the price target from $220 to $205.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 10:28 am

MAT

Roth MKM analyst Eric Handler has downgraded Mattel (NASDAQ:MAT) from Buy to Neutral and reduced the price target from $24 to $20, indicating a more cautious outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 10:26 am

MU

Piper Sandler analyst Harsh Kumar has upgraded Micron Technology (NASDAQ:MU) from Neutral to Overweight and increased the price target from $70 to $95, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 10:25 am

ACI

Telsey Advisory Group analyst Joseph Feldman has reiterated a 'Market Perform' rating on Albertsons Companies (NYSE:ACI) and maintained a price target of $27.25.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 10:14 am

WDAY

Keybanc analyst Jason Celino has initiated coverage on Workday (NASDAQ:WDAY) with an Overweight rating and set a price target of $310.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 10:11 am

TYL

JMP Securities analyst Trevor Walsh has reinstated Tyler Technologies (NYSE:TYL) with a Market Outperform rating and set a price target of $490.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 10:09 am

INO

JMP Securities analyst Roy Buchanan has initiated coverage on Inovio Pharmaceuticals (NASDAQ:INO) with a Market Outperform rating and a price target of $1.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 10:06 am

ANTX

JMP Securities analyst Roy Buchanan has initiated coverage on AN2 Therapeutics (NASDAQ:ANTX) with a Market Outperform rating and set a price target of $30.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 10:03 am

XENE

Citigroup analyst David Hoang has initiated coverage on Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy rating and set a price target of $62.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 9:47 am